| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BMS-345541 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |